Outcomes in COVID-19 goflikicept studies

0 0.5 1 1.5+ All studies -135% 1 247 Improvement, Studies, Patients Relative Risk Mortality -135% 1 247 RCTs -135% 1 247 Late -135% 1 247 Goflikicept for COVID-19 c19early.org November 2025 Favorsgoflikicept Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -135% 2.35 [0.93-5.92] death 14/123 6/124 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Late treatment -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk All studies -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk 1 goflikicept COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Effect extraction pre-specified(most serious outcome) Favors goflikicept Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -135% 2.35 [0.93-5.92] 14/123 6/124 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Late treatment -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk All studies -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk 1 goflikicept COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Favors goflikicept Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -135% 2.35 [0.93-5.92] death 14/123 6/124 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Late treatment -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk All studies -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk 1 goflikicept COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Effect extraction pre-specified(most serious outcome) Favors goflikicept Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -135% 2.35 [0.93-5.92] death 14/123 6/124 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Late treatment -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk All studies -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk 1 goflikicept COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Effect extraction pre-specified(most serious outcome) Favors goflikicept Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -135% 2.35 [0.93-5.92] 14/123 6/124 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Late treatment -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk All studies -135% 2.35 [0.93-5.92] 14/123 6/124 135% higher risk 1 goflikicept COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.069 Favors goflikicept Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -135% 2.35 [0.93-5.92] death 14/123 6/124 Improvement, RR [CI] Treatment Control Samsonov (DB RCT) 0% 1.00 [0.64-1.55] no improv. 30/124 30/124 Samsonov (DB RCT) 3% 0.97 [0.66-1.43] no improv. 36/124 37/124 Goflikicept COVID-19 outcomes c19early.org November 2025 Favors goflikicept Favors control